Understanding Liver Cancer: Symptoms, Diagnosis, Treatment, and Living With the Disease

Liver cancer can feel frightening, especially when the diagnosis is new. This guide explains what liver cancer is, what causes it, how doctors diagnose and treat it, and what patients and families can do next. The focus is on primary liver cancer, which means cancer that starts in the liver, most often hepatocellular carcinoma.

What is Liver Cancer?

Liver cancer is a cancer that starts in the liver. Most primary liver cancers are hepatocellular carcinoma, or HCC, while a smaller group are intrahepatic bile duct cancers, also called intrahepatic cholangiocarcinoma. This is different from cancer that began elsewhere and later spread to the liver (National Cancer Institute, 2025).

When doctors say liver cancer, they usually mean primary liver cancer. HCC begins in the main liver cells, while intrahepatic cholangiocarcinoma begins in small bile ducts inside the liver. The distinction matters because treatment and outlook can differ. Many cases arise in a liver already affected by chronic inflammation or scarring, so doctors often have to manage both the tumor and the underlying liver disease at the same time (National Cancer Institute, 2025; Mauro et al., 2025).

How common is Liver Cancer?

Liver cancer is one of the most serious cancers worldwide. In 2022, there were an estimated 866,136 new cases and 758,725 deaths globally, making it the sixth most commonly diagnosed cancer and the third leading cause of cancer death. The burden is especially high in parts of Asia and sub Saharan Africa (Global Cancer Observatory, 2024; Mauro et al., 2025).

Liver cancer is more common in men than in women, and global patterns are changing. Viral hepatitis remains a major cause, but in many countries more cases are now linked to obesity, diabetes, and metabolic dysfunction associated steatotic liver disease. That shift matters because prevention increasingly depends not only on vaccination and antiviral care, but also on long term liver and metabolic health (Mauro et al., 2025; Global Cancer Observatory, 2024).

What causes Liver Cancer?

Liver cancer usually develops after years of ongoing liver injury. Chronic inflammation can lead to fibrosis and cirrhosis, and repeated cell damage raises the chance of genetic mistakes that allow cancer to grow. Not every person with liver disease gets liver cancer, but some risks clearly increase the chance (National Cancer Institute, 2025; Mauro et al., 2025).

The strongest global drivers are chronic hepatitis B and chronic hepatitis C. The National Cancer Institute notes that these infections are involved in at least 80 percent of HCC cases worldwide. Hepatitis B can increase risk even without cirrhosis, while hepatitis C more often raises risk through long term scarring. Cirrhosis from any cause is a major warning sign, and alcohol related liver disease adds further risk (National Cancer Institute, 2025).

Metabolic disease is now a major part of the picture. Obesity, type 2 diabetes, and metabolic dysfunction associated steatotic liver disease can lead to inflammation, fibrosis, and cirrhosis. In some people, cancer can develop even before cirrhosis is fully established, although risk is usually highest once scarring is advanced (Mauro et al., 2025; National Cancer Institute, 2025).

Other recognized risks include aflatoxin exposure, smoking, and certain inherited conditions such as hereditary hemochromatosis, Wilson disease, and alpha 1 antitrypsin deficiency. Risk is not destiny, but if you already have hepatitis, cirrhosis, or advanced fatty liver disease, it is wise to ask whether specialist follow up or surveillance is appropriate for you (National Cancer Institute, 2025).

What are the symptoms of Liver Cancer?

Liver cancer often causes no symptoms at first. When symptoms do appear, they may include pain in the upper abdomen, loss of appetite, early fullness, weight loss, jaundice, tiredness, nausea, abdominal swelling, or a lump under the right ribs. These symptoms can also happen with other liver problems, so they always need proper assessment (National Cancer Institute, 2024).

Early liver cancer may be found on a scan before it causes obvious problems. When symptoms develop, they often reflect either tumor growth or worsening liver function. Common warning signs include right sided abdominal pain, pain near the right shoulder blade, swelling of the abdomen, jaundice, dark urine, pale stools, itching, easy bruising, unusual fatigue, and unexplained weight loss (National Cancer Institute, 2024).

These symptoms do not prove that someone has cancer, but they should not be ignored, especially in people with hepatitis B, hepatitis C, cirrhosis, heavy alcohol use, or fatty liver disease. In that setting, new symptoms deserve timely medical review.

How is Liver Cancer diagnosed?

Liver cancer is diagnosed using a combination of history, blood tests, imaging, and sometimes biopsy. Doctors also assess how well the liver is functioning, because treatment decisions depend on both the tumor and the health of the liver. Staging shows whether the cancer is localized, involves blood vessels, or has spread (National Cancer Institute, 2024; Reig et al., 2022).

Blood tests may include liver function, clotting, hepatitis testing, and alpha fetoprotein, or AFP. AFP can support the diagnosis, but it is not definitive. Some people with liver cancer have high AFP, others do not, and noncancerous liver disease can also raise it (National Cancer Institute, 2024).

Imaging is central. Ultrasound may find a suspicious lesion, but diagnosis often depends on contrast CT or MRI. In classic HCC arising in a high risk liver, experienced teams can sometimes diagnose the cancer from imaging alone. A biopsy may be needed when the pattern is not typical or when doctors need to confirm the subtype (National Cancer Institute, 2025; Vogel et al., 2025).

For HCC, many teams use the Barcelona Clinic Liver Cancer system because it combines tumor burden, liver function, and physical condition to guide treatment. This helps explain why two people with similar tumor size may still receive different treatment plans if their liver reserve is different (Reig et al., 2022; Vogel et al., 2025).

How is Liver Cancer treated?

Liver cancer treatment depends on the cancer type, stage, tumor location, liver function, and overall fitness. Some treatments aim to cure the disease, especially in earlier stages, while others aim to control growth, relieve symptoms, and preserve quality of life. A liver tumor is never treated in isolation from the liver around it (National Cancer Institute, 2025; Vogel et al., 2025).

Surgery

Surgery offers the best chance of cure for selected patients. Resection removes the part of the liver containing the tumor and is most suitable when the disease is limited and the remaining liver is strong enough. Liver transplant can be an excellent option for some people with early stage HCC, especially when cirrhosis makes resection unsafe, because it removes both the tumor and the diseased liver (National Cancer Institute, 2025; Vogel et al., 2025).

Local liver directed treatments

When surgery is not suitable, local treatments can still work well. Ablation destroys small tumors with heat, freezing, alcohol, or electrical techniques and can be curative in selected cases. Artery based treatments such as transarterial embolization and transarterial chemoembolization are commonly used when the cancer is mainly confined to the liver but cannot be removed. Radiation therapy can also help control tumors or relieve symptoms in appropriate patients (National Cancer Institute, 2025; Reig et al., 2022).

Targeted therapy and immunotherapy

For advanced HCC, treatment has changed markedly in recent years. Modern first line options often use immunotherapy combinations, such as atezolizumab with bevacizumab or durvalumab with tremelimumab, for patients who are suitable candidates. Targeted drugs such as sorafenib, lenvatinib, regorafenib, cabozantinib, and ramucirumab also play important roles across different treatment lines. The best choice depends on liver function, bleeding risk, prior treatment, and the person's overall condition (Gordan et al., 2024; National Cancer Institute, 2025; Mauro et al., 2025).

What about chemotherapy?

For the commonest type, HCC, older style intravenous chemotherapy is no longer the standard treatment for most advanced cases because targeted therapy and immunotherapy have shown better results. Chemotherapy still matters more in some other primary liver cancers, especially intrahepatic cholangiocarcinoma, where systemic drug treatment remains important and targeted treatment is evolving for selected molecular changes (Tsung et al., 2024).

Side effects and what patients should ask

Side effects depend on the treatment used. Surgery can involve pain, bleeding risk, and a recovery period that may be longer in people with cirrhosis. Ablation and embolization can cause pain, fever, tiredness, and temporary worsening of liver tests. Targeted therapy may cause high blood pressure, diarrhea, mouth soreness, or hand and foot skin reactions, while immunotherapy can inflame organs such as the liver, lungs, bowel, thyroid, or skin. New symptoms during treatment should always be reported promptly (National Cancer Institute, 2025; Gordan et al., 2024).

Treatment plans may change over time, and that is normal. A patient may start with local therapy, later move to systemic treatment, or be considered for transplant after good control in selected settings. This is one reason multidisciplinary review matters so much in liver cancer care (Vogel et al., 2025; Mauro et al., 2025).

What is the outlook for people with Liver Cancer?

The outlook for liver cancer varies widely. It depends on stage, whether the cancer can be removed or transplanted, whether blood vessels are involved, how well the liver still works, and how the tumor responds to treatment. Statistics are useful for understanding patterns in groups, but they cannot predict exactly what will happen for one person (American Cancer Society, 2025; Mauro et al., 2025).

Earlier stage disease has a much better outlook than later stage disease. Patients who can have curative treatment such as resection, transplant, or ablation may do very well. The American Cancer Society notes that for early stage liver cancers treated with transplant, the five year survival rate is in the range of 60 to 70 percent (American Cancer Society, 2025).

Advanced HCC is also changing. Recent review literature notes that immune checkpoint inhibitor based combinations have pushed median overall survival beyond two years in some advanced disease settings, and a subset of patients experience longer durable responses. That does not mean advanced liver cancer is usually curable, but it does mean there are more options than in the past (Mauro et al., 2025; Gordan et al., 2024).

If you have been given a survival figure, try to treat it as background information rather than a verdict. Your own outlook may differ because of tumor biology, treatment access, liver function, and response to therapy. Asking what the numbers mean for your specific case is often more useful than focusing on a single percentage.

Living with Liver Cancer: Practical Tips for Patients and Families

Living with liver cancer means managing both the cancer and the liver. Helpful steps include keeping appointments, understanding the treatment goal, reporting symptoms early, protecting the liver from further injury, and using nutrition, pain support, and emotional care as part of treatment rather than as an afterthought (National Cancer Institute, 2025; Mauro et al., 2025).

Keep a written record of your diagnosis, stage, liver function, scan dates, medicines, and questions for clinic visits. Bring a family member or friend when possible. If appetite is poor or weight is falling, ask for dietitian input early rather than waiting until eating becomes much harder (National Cancer Institute, 2025).

Protecting the liver matters too. Avoid alcohol unless your clinician advises otherwise. Ask before using herbal products, detox supplements, or over the counter remedies, because some can worsen liver injury or interfere with treatment. If you have swelling, jaundice, confusion, fever, bleeding, or increasing abdominal pain, report it quickly, since these may reflect either cancer progression or worsening liver function (National Cancer Institute, 2025).

Emotionally, this diagnosis can be exhausting. Feeling frightened, angry, or numb does not mean you are coping badly. It means you are dealing with something hard. Support from counseling, peer groups, palliative care, faith leaders, or trusted relatives can make a real difference. Palliative care is specialized support for symptoms, stress, and quality of life at any stage of illness, not a sign that treatment has failed.

When should you talk to a cancer specialist about Liver Cancer?

You should speak with a cancer specialist as soon as liver cancer is suspected or diagnosed. Early specialist input helps confirm the exact tumor type, review the quality of imaging, assess liver function, and decide whether surgery, transplant, local therapy, systemic therapy, or a clinical trial is the best next step (Vogel et al., 2025; National Cancer Institute, 2025).

Specialist review is especially important if you have cirrhosis or hepatitis and a new liver lesion has been found, if AFP is rising, if the first opinion was based on limited imaging, or if you were told only that the cancer is inoperable without a detailed multidisciplinary discussion.

This is also where an online consultation can be genuinely useful. For many patients, especially those outside major cancer centers or those seeking a second opinion quickly, teleoncology can make it easier to review scans, pathology, and treatment options without delaying care. The goal is not to replace your local team, but to help you understand your choices clearly and move forward with more confidence.

Frequently Asked Questions about Liver Cancer

Is liver cancer curable?

Some liver cancers are curable, especially when found early and treated with resection, transplant, or ablation. Cure is less likely in advanced disease, but long term control is still possible for some patients, and treatment can often relieve symptoms and extend life meaningfully (National Cancer Institute, 2025; American Cancer Society, 2025).

Can liver cancer happen without cirrhosis?

Yes. Hepatitis B can lead to HCC even without cirrhosis, and some cancers linked to fatty liver disease can also occur before cirrhosis is established. Even so, cirrhosis remains one of the strongest overall risk factors (National Cancer Institute, 2025; Mauro et al., 2025).

Does a high AFP mean I definitely have liver cancer?

No. AFP can be helpful, but it is not a definitive test on its own. Some people with liver cancer have normal AFP, and some people with hepatitis or cirrhosis have raised AFP without cancer, which is why doctors interpret it together with imaging and the broader clinical picture (National Cancer Institute, 2024).

What is the difference between liver cancer and cancer that spread to the liver?

Primary liver cancer starts in the liver itself. Secondary liver cancer means a cancer began somewhere else, such as the colon, breast, or lung, and then spread to the liver. The treatments are different because doctors usually treat secondary liver cancer according to the original cancer type (National Cancer Institute, 2025).

Can liver cancer be prevented?

Many cases can be reduced through hepatitis B vaccination, treatment of hepatitis B and hepatitis C, lower alcohol exposure, healthier weight, diabetes control, and attention to chronic liver disease. Prevention is not always possible, but controlling known risks can make a meaningful difference (National Cancer Institute, 2025; Mauro et al., 2025).

References

American Cancer Society. 2025. Liver Cancer Survival Rates. American Cancer Society.
Global Cancer Observatory. 2024. Liver and Intrahepatic Bile Ducts Fact Sheet, Globocan 2022. International Agency for Research on Cancer.
Gordan JD et al. 2024. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal of Clinical Oncology. 42(15):1830 to 1850.
Mauro E et al. 2025. Hepatocellular carcinoma: Epidemiology, diagnosis and treatment. JHEP Reports. 7(12):101571.
National Cancer Institute. 2024. What Is Liver Cancer? National Cancer Institute.
National Cancer Institute. 2025. Liver Cancer Treatment. National Cancer Institute.
National Cancer Institute. 2025. Liver (Hepatocellular) Cancer Prevention (PDQ) Health Professional Version. National Cancer Institute.
Reig M et al. 2022. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 76(3):681 to 693.
Tsung C, Quinn PL, Ejaz A. 2024. Management of Intrahepatic Cholangiocarcinoma: A Narrative Review. Cancers. 16(4):739.
Vogel A et al. 2025. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow up. Annals of Oncology. 36(5):491 to 506.

Liver Cancer

On this page